NASDAQ:NTRP - Neurotrope Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.41 +0.01 (+0.11 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$9.41
Today's Range$9.3010 - $9.50
52-Week Range$3.40 - $9.94
Volume9,950 shs
Average Volume30,942 shs
Market Capitalization$74.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55

About Neurotrope (NASDAQ:NTRP)

Neurotrope logoNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate NRV II, LLC. The company was founded in 2012 and is based in New York, New York.

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005

Debt

Debt-to-Equity RatioN/A
Current Ratio12.59
Quick Ratio12.59

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book5.01

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-12,610,000.00
Net MarginsN/A
Return on Equity-89.39%
Return on Assets-81.21%

Miscellaneous

Employees5
Outstanding Shares7,900,000

Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope (NASDAQ:NTRP) issued its quarterly earnings results on Friday, August, 14th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03. View Neurotrope's Earnings History.

What price target have analysts set for NTRP?

2 brokerages have issued twelve-month target prices for Neurotrope's shares. Their predictions range from $15.00 to $16.00. On average, they expect Neurotrope's stock price to reach $15.50 in the next twelve months. View Analyst Ratings for Neurotrope.

Who are some of Neurotrope's key competitors?

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:
  • Dr. Daniel L. Alkon M.D., Co-Founder, Pres & Chief Scientific Officer (Age 76)
  • Mr. Robert Weinstein, CFO, Treasurer, Sec. Corp., Exec. VP & Compliance Officer (Age 58)
  • Mr. Charles S. Ramat, Consultant (Age 67)
  • Dr. Charles S. Ryan, CEO & Director (Age 54)
  • Mr. Jeffrey Benison, Director of Corp. Communications

Has Neurotrope been receiving favorable news coverage?

News stories about NTRP stock have trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neurotrope earned a daily sentiment score of 0.03 on Accern's scale. They also gave media headlines about the company an impact score of 48.37 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Neurotrope's major shareholders?

Neurotrope's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Cannell Peter B & Co. Inc. (3.43%). Company insiders that own Neurotrope stock include Bruce Bernstein, James Gottlieb and Kenneth J Gorelick. View Institutional Ownership Trends for Neurotrope.

Which institutional investors are buying Neurotrope stock?

NTRP stock was acquired by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc.. Company insiders that have bought Neurotrope stock in the last two years include Bruce Bernstein and Kenneth J Gorelick. View Insider Buying and Selling for Neurotrope.

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $9.41.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $74.62 million. Neurotrope employs 5 workers across the globe.

How can I contact Neurotrope?

Neurotrope's mailing address is 205 EAST 42ND STREET 17TH FLOOR, NEW YORK NY, 10017. The company can be reached via phone at 973-242-0005 or via email at [email protected]


MarketBeat Community Rating for Neurotrope (NTRP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurotrope (NASDAQ:NTRP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Neurotrope in the last 12 months. Their average twelve-month price target is $15.50, suggesting that the stock has a possible upside of 64.72%. The high price target for NTRP is $16.00 and the low price target for NTRP is $15.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.50$23.00$31.00$31.00
Price Target Upside: 64.72% upside163.46% upside344.76% upside344.76% upside

Neurotrope (NASDAQ:NTRP) Consensus Price Target History

Price Target History for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ:NTRP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Maxim GroupInitiated CoverageBuy$16.00HighView Rating Details
3/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$15.00MediumView Rating Details
5/2/2017AegisReiterated RatingBuy$31.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Neurotrope (NASDAQ:NTRP) Earnings History and Estimates Chart

Earnings by Quarter for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ:NTRP) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.68 EPS
Next Year EPS Consensus Estimate: $-1.88 EPS

Neurotrope (NASDAQ NTRP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.79)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.43)ViewN/AView Earnings Details
11/14/2016Q3 2016($2.56)ViewN/AView Earnings Details
8/15/2016Q2 2016($1.60)ViewN/AView Earnings Details
5/13/2016Q1 2016($1.60)ViewN/AView Earnings Details
3/7/2016Q4 2015($1.92)ViewN/AView Earnings Details
11/13/2015Q3 2015($2.88)($2.56)ViewN/AView Earnings Details
8/14/2015Q2 2015($0.08)($0.11)ViewN/AView Earnings Details
5/14/2015Q1 2015($2.88)($6.39)ViewN/AView Earnings Details
3/26/2015Q4 2014($5.75)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.10)($0.14)ViewN/AView Earnings Details
8/14/2014Q2 2014($2.88)ViewN/AView Earnings Details
5/15/2014Q1 2014($2.56)ViewN/AView Earnings Details
4/15/2014Q4 2013($2.56)ViewN/AView Earnings Details
11/14/2013Q3 2013($6.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Neurotrope (NASDAQ:NTRP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neurotrope (NASDAQ NTRP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 14.46%
Insider Trading History for Neurotrope (NASDAQ:NTRP)
Institutional Ownership by Quarter for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ NTRP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018James GottliebDirectorSell314$8.42$2,643.88View SEC Filing  
12/2/2016Bruce BernsteinDirectorBuy50,000$0.28$14,000.0050,000View SEC Filing  
11/23/2016Kenneth J GorelickDirectorBuy5,000$0.29$1,450.0010,000View SEC Filing  
8/26/2016Kenneth J GorelickDirectorBuy5,000$0.41$2,050.005,000View SEC Filing  
11/23/2015James GottliebDirectorBuy10,000$0.59$5,900.005,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neurotrope (NASDAQ NTRP) News Headlines

Source:
DateHeadline
 Analysts Expect Neurotrope (NTRP) Will Announce Earnings of -$0.39 Per Share Analysts Expect Neurotrope (NTRP) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 22 at 3:14 PM
UPDATE: Maxim Group Starts Neurotrope (NTRP) at BuyUPDATE: Maxim Group Starts Neurotrope (NTRP) at Buy
www.streetinsider.com - May 16 at 5:34 PM
Neurotrope (NTRP) Now Covered by Analysts at Maxim GroupNeurotrope (NTRP) Now Covered by Analysts at Maxim Group
www.americanbankingnews.com - May 16 at 3:40 PM
Neurotrope (NTRP) Downgraded by Zacks Investment Research to "Sell"Neurotrope (NTRP) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - May 11 at 9:53 AM
BRIEF-Neurotrope Inc - On May 4 Neurotrope Bioscience Executed A Services Agreement With Worldwide Clinical TrialsBRIEF-Neurotrope Inc - On May 4 Neurotrope Bioscience Executed A Services Agreement With Worldwide Clinical Trials
www.reuters.com - May 11 at 8:37 AM
Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimers PatientsNeurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimer's Patients
finance.yahoo.com - May 7 at 5:33 PM
Neurotrope (NTRP) Upgraded to "Hold" at ValuEngineNeurotrope (NTRP) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 11:06 PM
Neurotrope (NTRP) Lowered to "Strong Sell" at ValuEngineNeurotrope (NTRP) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - April 15 at 7:48 PM
Neurotrope Alzheimers Candidate Could Generate Revenue Beginning In 2024, Analyst SaysNeurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says
finance.yahoo.com - March 9 at 6:41 PM
Neurotrope (NTRP) Now Covered by Analysts at Roth CapitalNeurotrope (NTRP) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - March 8 at 10:37 AM
Neurotrope to Present at the Cowen and Company 38th Annual Health Care ConferenceNeurotrope to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - February 28 at 5:58 PM
Neurotrope to Present at BIO CEO & Investor ConferenceNeurotrope to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:59 AM
Neurotrope to Present at NobleCon 14th Annual Institutional Investor ConferenceNeurotrope to Present at NobleCon 14th Annual Institutional Investor Conference
finance.yahoo.com - January 25 at 9:52 AM
Neurotropes Bryostatin Improves Cognition in Patients with Advanced Alzheimers Disease Based on Further Analysis of Phase 2 Clinical Trial DataNeurotrope's Bryostatin Improves Cognition in Patients with Advanced Alzheimer's Disease Based on Further Analysis of Phase 2 Clinical Trial Data
finance.yahoo.com - January 5 at 9:31 AM
Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimers DiseaseNeurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease
finance.yahoo.com - December 19 at 9:25 AM
Neurotrope Appoints Charles S. Ryan as Chief Executive OfficerNeurotrope Appoints Charles S. Ryan as Chief Executive Officer
finance.yahoo.com - December 18 at 9:44 AM

SEC Filings

Neurotrope (NASDAQ:NTRP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Neurotrope (NASDAQ NTRP) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.